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Discrimination of oncogenic growth signals from normal growth signals is crucial for tumor
suppression. The transcription factor E2F, the main target of pRB, plays central role in cell
proliferation by activating growth-promoting genes. E2F also plays an important role in
tumor suppression by activating growth-suppressive genes such as pro-apoptotic genes. The
regulatory mechanism of the latter genes is not known in detail, especially in response to nor-
mal and oncogenic growth signals. E2F is physiologically activated by growth stimulation
through phosphorylation of pRB. In contrast, upon dysfunction of pRB, a major oncogenic
change, E2F is activated out of control by pRB, generating deregulated E2F activity. We show
here that the tumor suppressor TAp73 gene, which can induce apoptosis independently of p53,
responds to deregulated E2F activity, but not to physiological E2F activity induced by growth
stimulation in human normal fibroblasts. We identified E2F-responsive elements (ERE73s) in
TAp73 promoter that can specifically sense deregulated E2F activity. Moreover, RB1-deficient
cancer cell lines harbored deregulated E2F activity that activated ERE73s and the TAp73 gene,
which were suppressed by re-introduction of pRB. These results underscore the important role
of deregulated E2F in activation of the TAp73 gene, a component of major intrinsic tumor
suppressor pathways.
Introduction
Cell cycle progression is promoted not only by nor-
mal growth stimulation but also by abnormal growth
stimulation induced by oncogenic changes. In
response to such inappropriate cell cycle promotion,
cells can induce apoptosis or senescence to avoid
tumorigenesis (Lowe et al. 2004). The tumor suppres-
sors pRB and p53 play major roles in the intrinsic
tumor suppression mechanism (Sherr & McCormick
2002). Accordingly, defects in the RB pathway and
the p53 pathway are observed in almost all cancers
(Sherr 1996).
The transcription factor E2F, the main target of
pRB, plays essential roles in cell proliferation by reg-
ulating a group of growth-promoting genes (Dyson
1998). E2F consists of eight family members that are
divided into transcriptional activators (E2F1 to E2F3)
and transcriptional repressors (E2F4 to E2F8)
(DeGregori & Johnson 2006). Growth stimulation
activates cyclin-dependent kinases (CDKs), which
phosphorylate and inactivate pRB family proteins and
physiologically activates E2F to promote cell cycle
progression. In contrast, E2F can also induce expres-
sion of pro-apoptotic and growth-suppressive genes,
whose expression is inconvenient for cell proliferation
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(Dimri et al. 2000; Muller et al. 2001). It is not
known in detail how E2F regulates pro-apoptotic and
growth-suppressive genes in response to normal and
abnormal growth stimulation.
We previously reported that the tumor suppressor
p14ARF (hereafter ARF) gene, an upstream regulator
of p53, and the CDK inhibitor p27Kip1 gene, an
upstream regulator of pRB and E2F, are activated
by deregulated E2F activity caused by dysfunction
of pRB, but not by physiological E2F activity
induced by serum stimulation, that is, normal
growth stimulation, in human normal fibroblasts
(Komori et al. 2005; Ozono et al. 2009). These
observations suggest that there is a mechanism that
discriminates deregulated E2F activity from physio-
logical E2F activity to activate the tumor suppressor
genes, which activate the two major tumor suppres-
sor pathways. The distinct regulation of the genes
seems to be important to avoid tumorigenesis in
response to dysfunction of pRB, although allowing
normal cell proliferation in response to normal
growth stimulation.
The TP73 gene encodes two isoforms with oppo-
site functions. The TAp73 isoform, which contains
transactivation (TA) domain, is a homologue of p53
and can induce apoptosis independently of p53
(Kaghad et al. 1997; Stiewe & Putzer 2000). In con-
trast, the DNp73 isoform, which lacks the TA domain,
counteracts TAp73 and p53 and is anti-apoptotic. Dif-
ferent promoters regulate the expression of these two
isoforms. The TAp73 gene is thought to be a tumor
suppressor gene and is known to be a direct target of
E2F1 (Irwin et al. 2000; Lissy et al. 2000; Stiewe &
Putzer 2000). However, the regulatory mechanism of
the TAp73 gene by E2F1 has been examined using
cancer cell lines with over expression of E2F1 in most
cases and has not been analyzed in normal cells in
detail. In addition, it is not known how the TAp73
gene is regulated by E2F, especially in response to
physiological and deregulated E2F activity. In this
report, we examined the regulation of the TAp73 gene
by physiological and deregulated E2F activity in
human normal fibroblasts (HFFs) to further elucidate
the role of deregulated E2F in tumor suppression,
focusing on the pathway independent of the RB and
p53 pathways. We show that the TAp73 gene is acti-
vated by deregulated E2F activity, but not by physio-
logical E2F activity induced by growth stimulation in
HFFs. Moreover, isolated TAp73 promoter is acti-
vated in RB1-deficient cancer cell lines but not in
HFFs, underscoring the role of deregulated E2F in
tumor suppression.
Results
TAp73 gene is activated by deregulated E2F
activity, but not by physiological E2F activity
To explore the regulatory mechanism of the TAp73
gene by E2F, we examined the responsiveness of the
TAp73 gene to physiological and deregulated E2F
activity. In order to examine the responsiveness of the
TAp73 gene to dysfunction of pRB, a prototype of
oncogenic changes, we used normal cells (human fore-
skin fibroblasts; HFFs), and not cancer cell lines, which
have defects in the RB pathway in most cases. To
induce physiological E2F activity, we used serum for
normal growth stimulation of fibroblasts. To induce
deregulated E2F activity, we used ectopic expression
of E2F1 and forced inactivation of pRB by the D2-11
form or 2RG form of adenovirus E1a, which binds to
and inactivates all pRB family members but does not
interfere with CBP/p300. We also used knockdown
of pRB expression by shRNA against RB1 (shRB),
which has been successfully used in previous studies
(Komori et al. 2005; Ozono et al. 2009).
We first examined the responsiveness of the endog-
enous TAp73 gene to physiological E2F activity. HFFs
were starved of serum, restimulated with serum, and
the TAp73 mRNA levels were examined by RT-
PCR (Fig. 1A, left panel) and quantitative (q)RT-
PCR (Fig. 1B, left panel). Remarkably, TAp73 gene
expression was scarcely induced by serum stimulation
at 18 h after serum stimulation. In contrast, expression
of the CDC6 gene, whose growth-regulated expres-
sion is mainly mediated by E2F (Ohtani et al. 1998),
was clearly induced, indicating that E2F was physio-
logically activated under the serum-stimulated condi-
tion. These results suggest that physiological E2F
activity induced by serum stimulation scarcely activates
the TAp73 gene in HFFs.
We next examined whether the TAp73 gene is acti-
vated by deregulated E2F activity in HFFs. The cells
were infected with recombinant adenovirus expressing
E2F1 or the D2-11 form of adenovirus E1a, and the
TAp73 mRNA level was similarly examined by RT-
PCR and qRT-PCR. The expression of the TAp73
gene was dramatically induced by ectopically expressed
E2F1 and adenovirus E1a (Fig. 1A, left panel and
Fig. 1B, middle panel). This suggests that not only
ectopically expressed E2F1, but also endogenous E2F
deregulated by forced inactivation of pRB family pro-
teins can activate the TAp73 gene. To examine
whether forced inhibition of pRB alone generates de-
regulated E2F activity that activates the TAp73 gene,
HFFs were infected with recombinant adenovirus
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expressing shRB, which successfully down-regulated
pRB expression (Fig. 1A, right panel). TAp73 gene
expression was induced by shRB (Fig. 1A, left panel
and Fig. 1B, right panel), indicating that forced down-
regulation of pRB expression alone is sufficient to acti-
vate endogenous E2F to activate the TAp73 gene. We
also examined whether expression of the NOXA, p21,
PUMA, and 14-3-3r genes, which are targets of
TAp73, is specifically induced by deregulated E2F
activity in HFFs (Fig. 1B). Expression of all the genes
was not induced at all by serum stimulation (Fig. 1B,
left panel) and was induced, although slightly at this
time point, by ectopically expressed E2F1 (Fig. 1B,
middle panel) and shRB (Fig. 1B, right panel) in
HFFs. Expression of the 14-3-3r gene was induced
more than 20-fold and that of the NOXA gene was
slightly induced by adenovirus E1a (Fig. 1B, middle
panel). However, expression of the p21 and PUMA
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genes was not induced by adenovirus E1a. This could
be due to additional functions of E1a to inactivation of
pRB family proteins. E1a is reported to suppress acti-
vation of p21 promoter by TAp73 (Das et al. 2003).
Similar effect of E1a for PUMA gene expression is
expected, because E1a is reported to suppress p53-
mediated induction of p21 and PUMA gene expression
(Savelyeva & Dobbelstein 2011), and TAp73 is a p53
family member.
To confirm that expression of the TAp73 gene is not
induced by serum stimulation all through the cell cycle,
we monitored TAp73 gene expression by qRT-PCR
until 28 h after serum stimulation (Fig. 1C). TAp73
gene expression was not induced till 28 h, when per-
centage of cells in G2/M decreased and that in G0/G1
increased (next G1 phase) (Fig. 1C). These results indi-
cate that TAp73 gene expression is not induced by
serum stimulation in HFFs.
To further analyze E2F regulation of the TAp73
gene in normal cells, we also examined regulation of
TAp73 promoter by E2F in HFFs. For this purpose,
we isolated TAp73 promoter (892 to +52) and
examined its responsiveness to serum stimulation,
ectopically expressed E2F1 and the 2RG form of
adenovirus E1a. Consistent with the endogenous
gene expression, the TAp73 promoter was not acti-
vated by serum stimulation at all under conditions in
which CDC6 promoter was clearly activated at 20 h
after serum stimulation (Fig. 1D). We also monitored
TAp73 promoter activity until 28 h after serum stim-
ulation (Fig. 1E). Consistent with the endogenous
gene expression, TAp73 promoter activity was not
induced at any time points till 28 h. In contrast, the
TAp73 promoter was dramatically activated by
ectopically expressed E2F1 and adenovirus E1a to a
far greater extent than that of the CDC6 promoter
Figure 1 TAp73 gene is activated by deregulated E2F activity but not by physiological E2F activity in human normal fibroblasts.
(A) Left panel: Endogenous TAp73 gene expression is induced by deregulated E2F activity but not by physiological E2F activity.
For serum stimulation experiments, human foreskin fibroblasts (HFFs) were starved of serum for 2 days, either left serum-starved
(Starved) or re-stimulated with serum (Serum) for 18 h, and harvested. For experiments with ectopically expressed E2F1 and the
D2-11 form of adenovirus E1a, which inactivates all pRB family proteins but not p300/CBP, HFFs were infected with recombi-
nant adenovirus expressing E2F1 (Ad-E2F1) or the D2-11 form of E1a (Ad-E1A), or control virus (Ad-Con) at MOI 200, cul-
tured under serum-starved conditions for 1 day and harvested. For pRB knockdown experiments, HFFs were infected with
recombinant adenovirus expressing shRNA against RB1 (Ad-shRB) or control virus (Ad-shCon) at MOI 500, cultured under
serum-starved conditions for 2 days, restimulated with serum for 18 h, and harvested. The mRNA levels were examined by RT-
PCR. CDC6 is a positive control for serum stimulation and GAPDH is an internal control. Right panel: Down-regulation of
pRB expression by shRB. pRB expression was examined by Western blotting. U-2 OS and C-33 A are positive and negative
controls, respectively. a-tubulin is an internal control. (B) qRT-PCR analysis of the same set of samples in (A), including the
NOXA, p21, PUMA and 14-3-3r genes. (C) TAp73 gene expression is not induced by serum stimulation in HFFs all through the
cell cycle. The expression levels of the TAp73 and CDC6 genes were examined by qRT-PCR and were normalized by that of
GAPDH (upper panel). Cell cycle distribution of HFFs was examined by FACS analysis based on DNA content (lower panel).
(D) The TAp73 promoter is not activated by serum stimulation. The TAp73 reporter plasmid, p73(-892)-Luc, was transfected into
HFFs with pCMV-b-gal as an internal control by lipofection, cultured under serum-starved conditions for 2 days, restimulated
with serum for 20 h and harvested. Luciferase activity was normalized to b-galactosidase activity. pCDC6-Luc/wt and pARF
(-66)-Luc were used as positive and negative controls, respectively, for serum stimulation. (E) The TAp73 promoter is not acti-
vated by serum stimulation all through the cell cycle of HFFs. HFFs were transfected with p73(-892)-Luc, pCDC6-Luc/wt or
pCDC6-Luc/mt along with pCMV-b-gal, starved of serum for 2 days and restimulated with serum. The cells were harvested at
indicated time points and assayed for luciferase activity normalized by b-galactosidase activity. (F, G) The TAp73 promoter is acti-
vated by deregulated E2F activity induced by dysfunction of pRB. HFFs were transfected with reporter plasmids, 20 ng of expres-
sion vector for E2F1 (F), or the 2RG form of adenovirus E1a (G), which inactivates all pRB family proteins but not p300/CBP,
and pCMV-b-gal, cultured under serum-starved conditions for 1 day, and assayed. pCDC6-Luc/wt and pARF(-736)-Luc were
used as positive controls and pARF(-66)-Luc was used as a negative control to monitor deregulated E2F activity. (H) The TAp73
promoter is not activated by etoposide treatment in HFFs. HFFs were transfected with p73(-892)-Luc and pCMV-b-gal along
with the expression vector for E2F1, or control plasmid, cultured in the presence of serum for 1 day. The cells transfected with
the control plasmid were treated with etoposide (50 lM) or DMSO (vehicle), and harvested after 20 h. A p53-responsive reporter,
pRGC-Luc, was used as a positive control and p73(-118)-Luc and pGL3-Prom were used as negative controls. (I) cH2A.X is
induced by etoposide treatment but scarcely induced by deregulated E2F activity in HFFs. HFFs were infected with recombinant
adenovirus expressing E2F1 or the D2-11 form of E1a at MOI 200 that activates the TAp73 promoter to a similar extent to that
in transient transfection assay, or treated with etoposide (50 lM) as described in the legend to Fig. 1G. cH2A.X was detected by
Western blotting. b-actin is an internal control.
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(Fig. 1F,G). Thus, regulation of the TAp73 promoter
by E2F is similar to that of the ARF(-736) promoter,
which has been shown to be activated by deregulated
E2F activity, but not by physiological E2F activity
induced by serum stimulation in human normal
fibroblasts (Komori et al. 2005).
Taken together, these results indicate that the
TAp73 gene is activated by deregulated E2F activity
caused by forced inactivation of pRB, but not by
physiological E2F activity induced by serum stimula-
tion in HFFs. Thus, regulation of the TAp73 gene is
distinct from that of growth-related E2F targets,
which are activated by both physiological and dereg-
ulated E2F activity.
TAp73 promoter is not activated by etoposide
treatment in HFFs
It has been reported that ectopically expressed E2F1
can induce DNA damage (Rogoff et al. 2004) and
that TAp73 promoter is activated by treatment with
DNA damaging reagent in cancer cell lines (Pediconi
et al. 2003). These reports suggest a possibility that
deregulated E2F activity may induce DNA damage,
which in turn activates the TAp73 promoter. To
address this possibility, we examined the responsive-
ness of the TAp73 promoter to treatment of HFFs
with etoposide, a DNA damaging reagent, which is
known to activate the TAp73 gene in some cancer
cell lines (Pediconi et al. 2003; Urist et al. 2004). As
a positive control, which is known to be activated by
DNA damage, we used the p53-responsive reporter
RGC-Luc, which contains p53 binding sites from
ribosomal gene cluster (RGC) (Kern et al. 1991)
upstream of murine c-fos core promoter.
Under the condition that RGC-Luc was clearly
activated by etoposide treatment in HFFs, the TAp73
promoter was not activated by etoposide treatment at
all (Fig. 1H). However, ectopically expressed E2F1
dramatically activated the TAp73 promoter. RGC-Luc
was activated by ectopically expressed E2F1 to a similar
extent as that by etoposide treatment. This activation
of RGC-Luc by ectopically expressed E2F1 is likely to
be mediated through induction of ARF, an upstream
activator of p53 (Komori et al. 2005).
In addition, cH2A.X, a marker of DNA damage,
was detected after the treatment of HFFs with etopo-
side, but not upon generation of deregulated E2F
activity by ectopically expressed E2F1 or adenovirus
E1a under these experimental conditions (Fig. 1I).
These results suggest that activation of the TAp73
promoter by deregulated E2F activity is mainly medi-
ated through deregulated E2F itself, and not through
DNA damage in HFFs.
Identification of E2F responsive elements of the
TAp73 promoter
To further analyze E2F regulation of the TAp73 pro-
moter, we explored E2F responsive elements of the
TAp73 promoter (ERE73s), which may play impor-
tant roles in discriminating between physiological and
deregulated E2F activity in HFFs. We constructed a
series of 5′ deletion mutants of the TAp73 promoter
and examined their responsiveness to ectopically
expressed E2F1 by a reporter assay. A remarkable
decrease in E2F1-responsiveness was observed
between (295) to (218) and (218) to (118),
suggesting that E2F responsive elements are located in
these two regions (Fig. 2A). To narrow down the
location of E2F responsive elements, we isolated each
region and divided them into two parts (Fig. 2B, mid-
dle), connected to a heterologous core promoter of
ARF, ARF(-66) (Komori et al. 2005), and examined
their E2F1-responsiveness (Fig. 2C). Regions (295
to 263) and (159 to 112) were highly activated,
suggesting that the main E2F responsive elements are
located in these regions. We further divided each of
these regions into two parts (Fig. 2B, bottom) and
found that all of the four subregions were activated by
ectopically expressed E2F1 (Fig. 2D) and/or adenovi-
rus E1a (Fig. 2E). These regions contain GC stretches,
which have been shown to be important for respon-
siveness of the ARF promoter to deregulated E2F
activity (Fig. 3A) (Komori et al. 2005). Two point
mutations in the consecutive GC sequence (Fig. 3B)
almost abolished the responsiveness of each element to
ectopically expressed E2F1 (Fig. 2F) and adenovirus
E1a (Fig. 2G), suggesting that these GC stretches are
important for responsiveness of ERE73s to deregulat-
ed E2F activity.
We refer to sequences (295 to 278), (277 to
263), (159 to 136) and (135 to 112) as
ERE73-1 to 4, respectively. Three identified ERE73s
(1, 3, and 4) contain the functional E2F sites in TAp73
promoter that were showed to bind to E2F1 by elec-
trophoretic mobility shift assay (Seelan et al. 2002).
Because the degree of activation of each ERE73 was
relatively small and may hinder further analyses, we
used the (295 to 263) and (159 to 112) regions,
referred to as ERE73-(1+2) and ERE73-(3+4),
respectively, for further analyses (Figs 2B and 3C).
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ERE73s sense deregulated E2F activity but not
physiological E2F activity in HFFs
To explore whether ERE73s are responsible for dis-
criminating between physiological and deregulated
E2F activity, we examined the responsiveness of
ERE73-(1+2) and ERE73-(3+4) to deregulated and
physiological E2F activity in HFFs. ERE73-(1+2)
and ERE73-(3+4) were activated by ectopically
expressed E2F1 and by adenovirus E1a, and the
introduction of the same mutations as that of each
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Figure 2 Identification of the E2F-responsive elements of the TAp73 promoter (ERE73s). (A) A set of 5′ deletion mutants of the
TAp73 promoter was examined for E2F1-responsiveness as described in the legend to Fig. 1F. (B) Location of ERE73s in the
TAp73 promoter. (C–E) Isolated fragments of the TAp73 promoter were combined with pARF(-66)-Luc, and their responsiveness
to E2F1 (C, D) and E1a (E) was examined as described in the legend to Fig. 1F,G. (F, G) Mutant forms (m) of the isolated frag-
ments were similarly examined for responsiveness to E2F1 (F) and the 2RG form of adenovirus E1a (G).
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(Fig. 4A,B). Consistent with the TAp73 promoter,
ERE73-(1+2) and ERE73-(3+4) did not show any
clear responsiveness to serum stimulation (Fig. 4C).
To examine whether ERE73s are necessary for
sensing deregulated E2F activity in the TAp73 pro-
moter, we introduced the same mutations as that of
each ERE73 mutant into the TAp73 promoter
(Fig. 3B). Introduced mutations almost abolished the
responsiveness of the TAp73 promoter to ectopically
expressed E2F1 (Fig. 4D) and adenovirus E1a
(Fig. 4E). Taken together, ERE73s play major roles
in discriminating between physiological and deregu-
lated E2F activity in the TAp73 promoter.
Among the eight E2F family members, E2F1
through E2F3 are thought to be activator E2Fs. We
thus examined contribution of the each activator E2F
to activation of the TAp73 promoter. We examined
the responsiveness of the TAp73 promoter to E2F1
through E2F3, which were expressed from the same
amount of expression vectors with the same back-
bone in HFFs (Fig. 4F). The TAp73 promoter was
dramatically activated by ectopically expressed E2F1,
slightly activated by E2F2 and scarcely activated by
E2F3, in a similar manner to ARF promoter, a pro-
apoptotic E2F target promoter, which specifically
senses deregulated E2F activity. The results seem rea-
sonable because, in general, E2F1 is regarded as a
strong activator for pro-apoptotic genes and E2F3 for
growth-related gene, E2F2 being at the middle.
To investigate binding of deregulated and physio-
logical E2F1 to TAp73 promoter in vivo, we carried
out chromatin immunoprecipitation (ChIP) assay,
using serum-starved HFFs (Fig. 4G). Upon serum
stimulation, binding of E2F1 to TAp73 promoter was
not increased compared with serum-starved condition.
Under the same condition, binding of E2F1 to CDC6
promoter was clearly increased. In contrast, binding of
E2F1 to both TAp73 promoter and CDC6 promoter
was clearly increased upon ectopic expression of E2F1
or adenovirus E1a, which forcedly inactivates all pRB
family members and deregulates endogenous E2F.
These results suggest that deregulated E2F1, but not
physiologically activated E2F1 induced by serum stim-
ulation, can bind to TAp73 promoter.
RB1-deficient cancer cell lines harbor deregulated
E2F activity that activates the TAp73 gene
The TAp73 gene is activated by deregulated E2F
activity caused by dysfunction of pRB. However,
accumulation of oncogenic changes may tolerate
TAp73 gene activation, leading to tumorigenesis. If
this is the case, cancer cells may retain deregulated
E2F activity, which activates the TAp73 gene. To
address this issue, we examined whether RB1-
deficient cancer cell lines (5637, Saos-2, and C-33 A)
harbored the deregulated E2F activity.
We first examined whether ERE73s, which specif-
ically sense deregulated E2F activity in HFFs, are
activated in the cancer cell lines by reporter assay.
ERE73-(1+2) and ERE73-(3+4) showed higher
activity than those mutants, which almost lost the
E2F responsiveness, in all cancer cell lines tested, but
not in HFFs (Fig. 5A). These results suggest that
ERE73s are activated in the cancer cell lines but not
in HFFs. When we introduced a constitutively active
form of pRB (PSM.7-LP) (Knudsen & Wang 1997),
the activity of ERE73-(1+2) and ERE73-(3+4) was
suppressed in the cancer cell lines but not in HFFs
(Fig. 5A). Under the same conditions, CDC6 pro-
moter activity was suppressed in HFFs, indicating that
physiological E2F activity was suppressed by PSM.7-
LP in HFFs. Similarly, the activity of the TAp73 pro-
moter was suppressed by PSM.7-LP in the cancer cell
lines, but not in HFFs (Fig. 5B). These results suggest
that the RB1-deficient cancer cell lines, but not
HFFs, retain deregulated E2F activity that activates
ERE73s and the TAp73 promoter. To confirm the
biological significance of the deregulated E2F activity
retained in the RB1-deficient cancer cell lines, we
next examined whether the endogenous TAp73 gene
is activated by deregulated E2F activity in the cancer
cell lines. For this purpose, we introduced PSM.7-LP
into the cancer cell lines using recombinant adeno-
ERE73–(1+2)m:  t t t t
ERE73–(3+4)m:  aa aa
ERE73–1m:                                             TTTGGaaCGCGTCGCTCC 
ERE73–1 (–278~ –295):                               TTTGGCGCGCGTCGCTCC
ERE73–3 (–159~ –136):                         TGCCTTCCCGCGCGCCGGGCTAAA
ERE73–2 (–263~ –277):                           TCCTTCCCGCCGCCT
ERE73–2m:                                             TCCTTCCaaCCGCCT
ERE73–3m:                                           TGCCTTCCCGaaCGCCGGGCTAAA
ERE73–4 (–112~ –135): GGCGGCCGCGGGCGTTAGCGCCTT 
ERE73–4m:                   GGCGGCCGCGGGCGTTAGCttCTT 
EREA: CTGAGCCGCCCGCGCGCGCGCCTCC
Typical E2F site:
EREK1:                                                       TTAGGCGCCGCT
EREK2:          TGCGTTGGCGGGTTCGC
ERE73–(1+2):     GGAGCGACGCGCGCCAAAAGGCGGCGGGAAGGA





Figure 3 Sequences of ERE73s compared with other E2F-
responsive elements. (A) Sequences of ERE73s were compared
with those of typical E2F sites, E2F responsive element of
p27Kip1 (EREKs) and p14ARF (EREA). (B, C) Mutations
introduced into ERE73s.
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Figure 4 E2F responsive elements of the TAp73 promoter are activated by deregulated E2F activity but not by physiological E2F
activity. (A–C) ERE73-(1+2), ERE73-(3+4), and their mutants were examined for responsiveness to E2F1 (A), E1a (B), and
serum stimulation (C), as described in the legend to Fig. 1F,G, and D, respectively. (D, E) ERE73s are responsible for sensing
deregulated E2F activity. p73(-892)-Luc and its point mutant, p73(-892)pm-Luc, were examined for responsiveness to E2F1 (D)
and E1a (E) as described in the legend to Fig. 1F,G. (F) The TAp73 promoter is preferentially activated by E2F1. p73(-892)-Luc
was examined for responsiveness to activator E2Fs (E2F1-E2F3), expressed from 5 ng of pENTR-CMV expression vector, along
with its core promoter p73(-118)-Luc, in HFFs. ARF(-736)-Luc, which specifically responds to deregulated E2F activity, was used
as a positive control. ARF(-13)-Luc was used as a negative control. (G) Binding of E2F1 to TAp73 promoter was increased by
either ectopic expression of E2F1 or adenovirus E1a, which inactivates all pRB family members and induces endogenous deregu-
lated E2F activity, but not by serum stimulation that physiologically activates E2F. HFFs were starved of serum, restimulated with
serum or infected with recombinant adenovirus as in the legend to Fig. 1A. ChIP assay was carried out with anti-E2F1 antibody.
anti-HA antibody is a negative control. Input is one 60th of the lysates.
© 2012 The Authors
Journal compilation © 2012 by the Molecular Biology Society of Japan/Blackwell Publishing Ltd.
Genes to Cells (2012) 17, 660–672
Distinct regulation of the TAp73 gene
667




0 4 8 12 16
Relative luciferase activity
0 8 16 24 0 2 4 6 8
Relative luciferase activity
Control PSM.7-LP












































C     P     C     P     C     P
5637 Saos-2 C-33 A
C     P     C     P     C     P
5637 Saos-2 C-33 A








































































5637 Saos-2 C-33 A
Figure 5 RB1-deficient cancer cell lines, but not human normal fibroblasts, harbor deregulated E2F activity that activates the
TAp73 gene. (A, B) ERE73s and the TAp73 promoter are activated in RB1-deficient cancer cell lines but not in HFFs. RB1-defi-
cient cancer cell lines (5637, Saos-2 and C-33 A) and HFFs were transfected with ERE73s or p73(-892)-Luc reporter plasmids
with an expression vector for the constitutively active form of pRB (PSM.7-LP). The cells were cultured for 1 day in the presence
of serum and harvested. pCDC6-Luc/wt and pCDC6-Luc/mt were used as a positive and negative control, respectively.
(C) Expression of PSM.7-LP was examined by Western blot analysis. (D) The endogenous TAp73 gene is activated in the RB1-
deficient cancer cell lines. The RB1-deficient cancer cell lines were infected with recombinant adenovirus expressing PSM.7-LP
or control virus at MOI 50, cultured in the presence of serum for 1 day, and harvested. The TAp73, CDC6, and NOXA mRNA
levels were examined by qRT-PCR. CDC6 is a positive control. The expression levels were adjusted by that of GAPDH as an
internal control. (E) The levels of cH2A.X in the RB1-deficient cancer cell lines were lower than that in HFFs treated with
etoposide. HFFs were treated with etoposide as described in the legend to Fig. 1H. cH2A.X was detected by Western blotting.
b-actin is an internal control. (F) Binding of E2F1 to endogenous TAp73 promoter was decreased by PSM.7-LP in the RB1-defi-
cient cancer cell lines. ChIP assay was carried out with anti-E2F1 antibody using the cancer cell lines introduced with PSM.7-LP
as in the legend to (C). CDC6 and b-actin are positive and negative control, respectively.
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virus (Fig. 5C) and examined TAp73 gene expression
by qRT-PCR (Fig. 5D). As expected, the expression
of the TAp73 gene was clearly suppressed by PSM.7-
LP in all the cancer cell lines. We also examined
whether TAp73 target gene expression was reduced
by PSM.7-LP in accordance with suppression of
TAp73 gene expression. NOXA gene expression was
reduced, at least to some extent, by PSM.7-LP in all
the cancer cell lines. These results suggest that the
TAp73 gene was activated by deregulated E2F in the
cancer cell lines and that the activation was reduced
upon re-introduction of pRB.
Most cancer cell lines are thought to harbor DNA
damage, which may activate the TAp73 gene. There-
fore, we compared the amount of cH2A.X in the
cancer cell lines with that in HFFs treated with eto-
poside. The result showed that the levels of cH2A.X
in the RB1-deficient cancer cell lines were lower
than that induced by etoposide treatment of HFFs
(Fig. 5E), which did not activate the TAp73 pro-
moter at all (Fig. 1H). These results suggest that the
TAp73 gene is mainly activated by deregulated E2F
activity, and not mainly through DNA damage, in
the cancer cell lines.
To further examine deregulated E2F activity in
RB1-deficient cancer cell lines, we examined binding
of deregulated E2F1 to endogenous TAp73 promoter
using ChIP assay (Fig. 5F). When we introduced
PSM.7-LP, binding of E2F1 to TAp73 promoter was
clearly decreased in 5637 and C-33 A cells and
slightly decreased in Saos-2 cells. These results suggest
that, in the RB1-deficient cancer cell lines, deregulat-
ed E2F1 bound to TAp73 promoter, which was sup-
pressed by re-introduction of pRB.
Taken together, these observations indicate that
the RB1-deficient cancer cell lines harbor deregulated
E2F activity that binds and activates the TAp73 gene.
Discussion
Our results clearly indicate that the tumor suppressor
TAp73 gene, a previously known pro-apoptotic E2F
target, is activated by deregulated E2F activity
induced by ectopically expressed E2F1 and forced
inactivation of pRB by adenovirus E1a or shRB, but
not by physiological E2F activity induced by serum
stimulation in human normal fibroblast HFFs. The
isolated TAp73 promoter reflected the responsiveness
of the TAp73 gene to deregulated and physiological
E2F activity. We showed that four ERE73s could
discriminate deregulated E2F activity from physiolog-
ical E2F activity. ChIP assay showed that deregulated
E2F1, but not physiological E2F1, bound to TAp73
promoter in vivo. Moreover, the RB1-deficient cancer
cell lines harbored deregulated E2F activity, which
activated ERE73s, the TAp73 promoter and the
endogenous TAp73 gene.
We previously reported that the tumor suppressor
ARF gene, the upstream regulator of the tumor sup-
pressor p53, and the CDK inhibitor p27Kip1 gene, an
upstream regulator of the tumor suppressor pRB are
specifically activated by deregulated E2F activity in
human normal fibroblasts (Komori et al. 2005; Ozono
et al. 2009). These results suggest that, upon loss of
pRB function, deregulated E2F activates the two
major tumor suppressor pathways (p53 and RB path-
ways) to protect cells from tumorigenesis. In this study,
we discovered that the tumor suppressor TAp73 gene
is activated by deregulated E2F activity, but not by
physiological E2F activity in HFFs. Accumulating
evidence indicates that the TAp73 gene also plays
major roles in tumor suppression. TAp73 can induce
apoptosis independently of p53 and plays major role in
E2F1-induced apoptosis in p53/ cells (Irwin et al.
2000). TP73+/ mice show an increased rate of spon-
taneous tumors (Flores et al. 2005). Specifically,
TAp73/ mice are tumor prone and sensitive to
chemical carcinogenesis (Tomasini et al. 2008). Taken
together, these observations indicate that the TAp73
gene is a bona fide tumor suppressor gene. Our results
underscore the role of deregulated E2F in tumor sup-
pression by activating the TAp73 pathway in addition
to the p53 and RB pathways.
It is reported that TAp73 gene expression is
induced by treatment with etoposide, a DNA damag-
ing agent, in the H116 colon cancer cell line through
stabilization of E2F1 (Urist et al. 2004). In contrast,
the TAp73 promoter was not activated by etoposide
treatment in HFFs (Fig. 1H) under the condition
where cH2A.X, a DNA damage marker, was
detected (Fig. 1I) and where a p53 reporter (RGC-
Luc) was activated (Fig. 1H). There seems to be a
difference in the regulation of the TAp73 gene in
response to DNA damage between cancer cell lines
and normal cells. Our results that the TAp73 gene is
activated by deregulated E2F activity in the RB1-
deficient cancer cell lines suggests that the TAp73
gene is also activated by deregulated E2F activity in
other cancer cell lines including ones retaining pRB.
It may be that stabilization of E2F1 by DNA damage
augments deregulated E2F activity and further acti-
vates TAp73 gene expression in cancer cell lines but
not in normal cells, which do not harbor deregulated
E2F activity. Alternatively, response of E2F1 to
© 2012 The Authors
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treatment with DNA damaging reagents may differ
between cancer cell lines and normal growing cells.
Further studies are required to elucidate differential
regulatory mechanism of TAp73 gene expression by
DNA damage in cancer cell lines and in normal
growing cells.
We identified the main E2F responsive elements
in the TAp73 promoter, ERE73s, which play central
role in discriminating between physiological and de-
regulated E2F activity in HFFs. Unexpectedly, the
core sequences of ERE73s were similar to that of a
typical E2F site (Fig. 3A), which is activated by both
physiological and deregulated E2F activity. This is in
contrast to the E2F-responsive element of ARF pro-
moter (EREA), which lacks T-stretches and is com-
posed of GC repeats and is similar to that of p27Kip1
promoter (EREK) (Fig. 3A). Indeed, the core
sequence of ERE73-1 completely fits the sequence of
a typical E2F site. Accordingly, we could not find
consensus sequences to specifically sense deregulated
E2F activity. It might be difficult for an E2F binding
site alone to discriminate between deregulated and
physiological E2F activity. The flanking sequence
around the E2F binding site could be important for
discriminating deregulated E2F activity from physio-
logical E2F activity. Alternatively, the location of the
E2F-responsive element in the promoter may be
important for the distinct regulation. In the case of
growth-related genes, E2F-responsive elements are
located very close to transcription start sites, mostly
within 100 bp. All of ERE73s are located more than
100 bp upstream of transcription start site. The loca-
tion of ERE73s may hinder activation by physiologi-
cally activated E2F. Another possibility is the
presence of other sequences in the promoter that
bind a factor(s), which cooperates with deregulated
E2F to activate transcription. Further studies are
required to address these issues.
The TAp73 promoter and ERE73s were activated
in the RB1-deficient cancer cell lines, but not in
HFFs. These results suggest that deregulated E2F
activity may exist specifically in cancer cells, but not
in normal growing cells. Current treatments of cancer
such as radiation and anti-cancer drugs preferentially
damage growing cells. Accordingly, they damage not
only cancer cells but also normal growing cells,
which may cause side effects that hamper radical
treatment of cancer. To avoid these side effects, it is
crucial to specifically target cancer cells. For this pur-
pose, it is important to discriminate cancer cells from
normal growing cells. Our findings that deregulated
E2F activity exists in the RB1-deficient cancer cells
but not in growing HFFs suggest that deregulated
E2F activity may serve as a useful indicator to dis-
criminate cancer cells from, at least, normal growing
fibroblasts. It might also be possible to apply deregu-
lated E2F activity to specifically target cancer cells.
Defects in the RB pathway are observed in almost all
cancers. It has yet to be determined whether cancer
cells, which retain pRB but have defect(s) in
upstream of pRB, also harbor deregulated E2F activ-
ity that activates the tumor suppressor genes.
Experimental procedures
Cell culture
Human normal fibroblasts (HFFs) and RB1-deficient cancer
cell lines (5637, Saos-2, and C-33 A) were maintained as
described previously (Ozono et al. 2009). To synchronize the
cell cycle, HFFs were cultured in Dulbecco’s modified Eagle
medium (DMEM) containing 0.1% fetal calf serum (FCS) for
2 days and were restimulated with serum by adding FCS to a
final concentration of 20%.
Plasmids
p73(-892)-Luc was generated by cloning the 892 to +52
region of the TAp73 promoter (AF235000) into pGL3-Basic
(Promega) using Sma I and Hind III sites. p73(-892)pm-Luc,
which has point mutations in all four E2F-responsive elements
in the TAp73 promoter (Fig. 3), was generated by site-direc-
ted mutagenesis. Expression vectors for E2F1, the 2RG form
of E1a, shRNA against RB1 (shRB), control shRNA (shCon),
a constitutively active form of pRB (PSM.7-LP), b-galactosi-
dase, and control plasmids were described previously (Ohtani
et al. 1998; Komori et al. 2005; Iwanaga et al. 2006). A series
of expression vectors for E2F1 through E2F3, pENTR-E2F1
through E2F3 were generated by cloning full length cDNAs
for E2F1 through E2F3 into pENTR/CMV, which were
made by cloning CMV promoter to poly(A) addition signal
cassette from pcDNA3 (Invitrogen, Carlsbad, CA, USA) into
pENTR/D-TOPO (Invitrogen). pGL3-Prom, pARF(-736)-
Luc, pARF(-66)-Luc, pCDC6-Luc/wt, and pCDC6-Luc/mt
were described previously (Komori et al. 2005). pARF(-13)-
Luc was generated by deleting the region between Bgl II and
Pst I of pARF(-66)-Luc. pRGC-Luc contains ribosomal gene
cluster (RGC) p53 binding sites (Kern et al. 1991), upstream
of murine c-fos core promoter-driven luciferase gene.
Transfection and reporter assay
Lipofection and luciferase assay were carried out as described
previously (Ohtani et al. 1998; Komori et al. 2005). All assays
were carried out at least three times and results are presented
as means ± SE.
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Recombinant adenovirus
Ad-Con, Ad-E2F1, Ad-12SE1A (D2-11), Ad-shCon and Ad-
shRB were described previously (Komori et al. 2005; Ozono
et al. 2009). Ad-PSM.7-LP was generated from the expression
vector for PSM.7-LP using ViraPower Adenoviral Expression
System (Invitrogen) according to the supplier’s protocol.
RNA interference
The target sequence for RB1 was described previously (Komori
et al. 2005).
Reverse transcription-PCR and quantitative (q)
RT-PCR
mRNA isolation and reverse transcription (RT)-PCR were
carried out as described previously (Komori et al. 2005). The
TAp73 cDNA was amplified by nested PCR, using primer
sets specific for TAp73. The first round amplification was 20
cycles with the primer set 5′-GGAGGCCGGCGTGGGGAA
GAT-3′ and 5′-GCTGGGTTGTGCGTAGGGCGAGTG-3′
(annealing temperature: 64.2 °C). The second round amplifi-
cation was 35 cycles with the primer set 5′-AGT
CCACCGCCACCTCCCCTGAT-3′ and 5′-CATTATTC
CCCCGGCTTGACTGG-3′ (annealing temperature: 58.8 °C).
Primer sets for CDC6 and GAPDH were described previously
(Komori et al. 2005). The PCR products of TAp73 and
CDC6 were detected using ethidium bromide staining and
that of GAPDH was detected using 32P incorporation using
image analyzer BAS 1500 (Fuji Film, Tokyo, Japan). qPCR
analysis was carried out using THUNDERBIRD SYBR
qPCR Mix (TOYOBO, Osaka, Japan) for CDC6, NOXA
and GAPDH, and SsoAdvanced SYBR Green Supermix (Bio-
Rad, Hercules, CA, USA) for TAp73. Primer sets for CDC6,
GAPDH, TAp73, NOXA, p21, PUMA and 14-3-3r are
described previously (Ferguson et al. 2000; Kartasheva et al.
2002; Yakovlev et al. 2004; Komori et al. 2005; Zhao et al.
2007; Sun et al. 2009).
Fluorescence-activated cell sorting analysis
Cells were fixed with 1x Fluorescence-activated cell sorting
(FACS) lysing solution (Becton Dickinson Franklin Lakes, NJ,
USA), washed with phosphate-buffered saline containing 0.5%
bovine serum albumin and 15 mM NaN3 and stained with
propidium iodide (50 lg/mL) containing RNase (50 lg/mL).
Cell samples were analyzed with a FACSCalibur (Becton
Dickinson).
Immunoblot analysis
Immunoblot analysis was carried out as described previously
(Iwanaga et al. 2001). The antibodies used were anti-pRB
[sc-50, Santa Cruz, 1:1000 with Canget Signal (TOYOBO,
La Jolla, CA, USA)], anti-phospho-Histone H2A.X (Ser139)
[05-636, Millipore, 1:1000 with Canget Signal (TOYOBO)],
anti-a-tubulin (DM1A, Oncogene Research Products, 1:500
with skim milk) and anti-b-actin (A1978, SIGMA, St Louis,
MO, USA; 1:2000 with skim milk).
Chromatin immunoprecipitation assay
ChIP assay was carried out as described (Komori et al. 2005)
using specific primer sets for TAp73 promoter (annealing tem-
perature: 55 °C) (Lau et al. 2009), CDC6 promoter (annealing
temperature: 60 °C) (Komori et al. 2005) and b-actin pro-
moter (annealing temperature: 59.2 °C) (Komori et al. 2005).
The amplification was 35 cycles for each PCR. Antibodies for
immunoprecipitating protein-DNA complexes were anti-E2F1
(sc-56662) and anti-HA (sc-7392) as a negative control (all
from Santa Cruz). Input is one 60th of the lysates.
Acknowledgements
We thank E. Knudsen for PSM.7-LP and J. Okuno for excel-
lent technical assistance. This work was supported by a Grant-
in-Aid for Science Research from the Ministry of Education,
Culture, Sports, Science and Technology of Japan (21570180
to K. O. and 22 2446 to E. O.), Hayashi Memorial Founda-
tion for Female Natural Scientists (09FB78 to E. O.) and Japa-
nese Association of University Woman (Yasui medical
fellowship 2009 to E. O.).
References
Das, S., El-Deiry, W.S. & Somasundaram, K. (2003) Regula-
tion of the p53 homolog p73 by adenoviral oncogene E1A.
J. Biol. Chem. 278, 18313–18320.
DeGregori, J. & Johnson, D.G. (2006) Distinct and overlap-
ping roles for E2F family members in transcription, prolifer-
ation and apoptosis. Curr. Mol. Med. 6, 739–748.
Dimri, G.P., Itahana, K., Acosta, M. & Campisi, J. (2000)
Regulation of a senescence checkpoint response by the
E2F1 transcription factor and p14ARF tumor suppressor.
Mol. Cell. Biol. 20, 273–285.
Dyson, N. (1998) The regulation of E2F by pRB-family pro-
teins. Genes Dev. 12, 2245–2262.
Ferguson, A.T., Evron, E., Umbricht, C.B., Pandita, T.K.,
Chan, T.A., Hermeking, H., Marks, J.R., Lambers, A.R.,
Futreal, P.A., Stampfer, M.R. & Sukumar, S. (2000) High
frequency of hypermethylation at the 14-3-3 r locus leads
to gene silencing in breast cancer. Proc. Natl Acad. Sci. USA
97, 6049–6054.
Flores, E.R., Sengupta, S., Miller, J.B., Newman, J.J.,
Bronson, R., Crowley, D., Yang, A., McKeon, F. & Jacks,
T. (2005) Tumor predisposition in mice mutant for p63 and
p73: evidence for broader tumor suppressor functions for
the p53 family. Cancer Cell 7, 363–373.
Irwin, M., Marin, M.C., Phillips, A.C., Seelan, R.S., Smith,
D.I., Liu, W., Flores, E.R., Tsai, K.Y., Jacks, T., Vousden,
© 2012 The Authors
Journal compilation © 2012 by the Molecular Biology Society of Japan/Blackwell Publishing Ltd.
Genes to Cells (2012) 17, 660–672
Distinct regulation of the TAp73 gene
671
K.H. & Kaelin, W.G. Jr. (2000) Role for the p53 homo-
logue p73 in E2F-1-induced apoptosis. Nature 407, 645–
648.
Iwanaga, R., Komori, H., Ishida, S., Okamura, N.,
Nakayama, K., Nakayama, K.I. & Ohtani, K. (2006)
Identification of novel E2F1 target genes regulated in cell
cycle-dependent and independent manners. Oncogene 25,
1786–1798.
Iwanaga, R., Ohtani, K., Hayashi, T. & Nakamura, M. (2001)
Molecular mechanism of cell cycle progression induced by
the oncogene product Tax of human T-cell leukemia virus
type I. Oncogene 20, 2055–2067.
Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.
C., Valent, A., Minty, A., Chalon, P., Lelias, J.M.,
Dumont, X., Ferrara, P., McKeon, F. & Caput, D. (1997)
Monoallelically expressed gene related to p53 at 1p36, a
region frequently deleted in neuroblastoma and other
human cancers. Cell 90, 809–819.
Kartasheva, N., Contente, A., Lenz-Stoppler, C., Roth, J. &
Dobbelstein, M. (2002) p53 induces the expression of its
antagonist p73DN, establishing an autoregulatory feedback
loop. Oncogene 21, 4715–4727.
Kern, S.E., Kinzler, K.W., Bruskin, A., Jarosz, D., Friedman,
P., Prives, C. & Vogelstein, B. (1991) Identification of p53
as a sequence-specific DNA-binding protein. Science 252,
1708–1711.
Knudsen, E.S. & Wang, J.Y. (1997) Dual mechanisms for the
inhibition of E2F binding to RB by cyclin-dependent
kinase-mediated RB phosphorylation. Mol. Cell. Biol. 17,
5771–5783.
Komori, H., Enomoto, M., Nakamura, M., Iwanaga, R. &
Ohtani, K. (2005) Distinct E2F-mediated transcriptional
program regulates p14ARF gene expression. EMBO J. 24,
3724–3736.
Lau, L.M., Wolter, J.K., Lau, J.T., Cheng, L.S., Smith, K.M.,
Hansford, L.M., Zhang, L., Baruchel, S., Robinson, F. &
Irwin, M.S. (2009) Cyclooxygenase inhibitors differentially
modulate p73 isoform in neuroblastoma. Oncogene 28,
2024–2033.
Lissy, N.A., Davis, P.K., Irwin, M., Kaelin, W.G. & Dowdy,
S.F. (2000) A common E2F-1 and p73 pathway mediates
cell death induced by TCR activation. Nature 407, 642–645.
Lowe, S.W., Cepero, E. & Evan, G. (2004) Intrinsic tumour
suppression. Nature 432, 307–315.
Muller, H., Bracken, A.P., Vernell, R., Moroni, M.C., Chris-
tians, F., Grassilli, E., Prosperini, E., Vigo, E., Oliner, J.D.
& Helin, K. (2001) E2Fs regulate the expression of genes
involved in differentiation, development, proliferation, and
apoptosis. Genes Dev. 15, 267–285.
Ohtani, K., Tsujimoto, A., Ikeda, M. & Nakamura, M.
(1998) Regulation of cell growth-dependent expression of
mammalian CDC6 gene by the cell cycle transcription fac-
tor E2F. Oncogene, 17, 1777–1785.
Ozono, E., Komori, H., Iwanaga, R., Ikeda, M.A., Iseki, S.
& Ohtani, K. (2009) E2F-like elements in p27Kip1 promoter
specifically sense deregulated E2F activity. Genes Cells 14,
89–99.
Pediconi, N., Ianari, A., Costanzo, A., Belloni, L., Gallo, R.,
Cimino, L., Porcellini, A., Screpanti, I., Balsano, C., Alesse,
E., Gulino, A. & Levrero, M. (2003) Differential regulation
of E2F1 apoptotic target genes in response to DNA damage.
Nat. Cell Biol. 5, 552–558.
Rogoff, H.A., Pickering, M.T., Frame, F.M., Debatis, M.E.,
Sanchez, Y., Jones, S. & Kowalik, T.F. (2004) Apoptosis
associated with deregulated E2F activity is dependent on
E2F1 and Atm/Nbs1/Chk2. Mol. Cell. Biol. 24, 2968–
2977.
Savelyeva, I. & Dobbelstein, M. (2011) Infection with E1B-
mutant adenovirus stabilizes p53 but blocks p53 acetylation
and activity through E1A. Oncogene 30, 86, 5–875.
Seelan, R.S., Irwin, M., van der Stoop, P., Qian, C., Kaelin,
W.G. Jr. & Liu, W. (2002) The human p73 promoter:
characterization and identification of functional E2F binding
sites. Neoplasia 4, 195–203.
Sherr, C.J. (1996) Cancer cell cycles. Science 274, 1672–1677.
Sherr, C.J. & McCormick, F. (2002) The RB and p53 path-
ways in cancer. Cancer Cell 2, 103–112.
Stiewe, T. & Putzer, B.M. (2000) Role of the p53-homo-
logue p73 in E2F1-induced apoptosis. Nat. Genet. 26, 464–
469.
Sun, Q., Ming, L., Thomas, S.M., Wang, Y., Chen, Z.G.,
Ferris, R.L., Grandis, J.R., Zhang, L. & Yu, J. (2009)
PUMA mediates EGFR tyrosine kinase inhibitor-induced
apoptosis in head and neck cancer cells. Oncogene 28, 2348–
2357.
Tomasini, R., Tsuchihara, K., Wilhelm, M., et al. (2008)
TAp73 knockout shows genomic instability with infertility
and tumor suppressor functions. Genes Dev. 22, 2677–2691.
Urist, M., Tanaka, T., Poyurovsky, M.V. & Prives, C. (2004)
p73 induction after DNA damage is regulated by check-
point kinases Chk1 and Chk2. Genes Dev. 18, 3041–3054.
Yakovlev, A.G., Giovanni, S.D., Wang, G., Liu, W., Stoica,
B. & Faden, A.I. (2004) BOK and NOXA are essential
mediators of p53-dependent apoptosis. J. Biol. Chem. 279,
28367–28374.
Zhao, Y., Katzman, R.B., Delmolino, L.M., et al. (2007) The
Notch regulator MAML1 interacts with p53 and functions
as a coactivator. J. Biol. Chem. 282, 11969–11981.
Received: 26 December 2011
Accepted: 19 April 2012
Genes to Cells (2012) 17, 660–672 © 2012 The Authors
Journal compilation © 2012 by the Molecular Biology Society of Japan/Blackwell Publishing Ltd.
E Ozono et al.
672
